Skip Navigation



Rheumatology Advance Access published online on May 25, 2006
Rheumatology, doi:10.1093/rheumatology/kel161
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
46/1/25    most recent
kel161v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kaji, K.
Right arrow Articles by Takehara, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaji, K.
Right arrow Articles by Takehara, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
Received February 6, 2006
Accepted April 4, 2006

Concise Report

Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy

K. Kaji 1, M. Fujimoto 1 *, M. Hasegawa 1, M. Kondo 1, Y. Saito 1, K. Komura 1, T. Matsushita 1, H. Orito 1, Y. Hamaguchi 1, K. Yanaba 2, M. Itoh 2, Y. Asano 3, M. Seishima 4, F. Ogawa 5, S. Sato 5, and K. Takehara 1

1 Department of Dermatology, Kanazawa University Graduate School of Medical Science, Ishikawa, Japan
2 Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan
3 Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan
4 Department of Dermatology, Ogaki Municipal Hospital, Gifu, Japan
5 Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

* To whom correspondence should be addressed.
M. Fujimoto, E-mail: fujimoto-m{at}umin.ac.jp


  Abstract

Objective. Myositis-specific autoantibodies (MSAs) are a useful tool in diagnosis, defining clinical subsets and predicting prognosis of dermatomyositis (DM) and polymyositis (PM). In this study, we identified a novel MSA reactive with 155 and 140 kDa nuclear proteins [anti-155/140 antibody (Ab)] and determined the clinical feature of DM patients positive for this autoantibody (autoAb).

Methods. Sera from 52 Japanese patients with DM, 9 with PM, 48 with systemic lupus erythematosus (SLE), 126 with systemic sclerosis and 18 with idiopathic interstitial pneumonia were examined by immunoprecipitation assays. Positive sera were further characterized by immunodepletion and immunofluorescence staining.

Results. Seven of the 52 (13%) Japanese patients with DM immunoprecipitated 155 and 140 kDa proteins from 35S-labelled K562 leukaemia cell extract. No patients with SLE, systemic sclerosis or idiopathic interstitial pneumonia as well as healthy controls were positive for this autoAb. Patients with anti-155/140 Ab developed heliotrope rash, Gottron's papules or sign and flagellate erythema significantly more frequently than those negative. Notably, internal malignancy was found at significantly higher frequency in those positive than those negative (71 vs 11%; P < 0.005). In contrast, none of these patients positive for this autoAb had interstitial lung disease.

Conclusions. This novel MSA is associated with cancer-associated DM and may serve as a diagnostic serological marker for this specific subset.

Keywords: Dermatomyositis; Myositis-specific autoantibodies; Malignancy; Interstitial lung disease.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Journal of RheumatologyHome page
G. ESPADA, J. A. MALDONADO COCCO, N. FERTIG, and C. V. ODDIS
Clinical and Serologic Characterization of an Argentine Pediatric Myositis Cohort: Identification of a Novel Autoantibody (anti-MJ) to a 142-kDa Protein
J Rheumatol, November 1, 2009; 36(11): 2547 - 2551.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
H. Gunawardena, Z. E. Betteridge, and N. J. McHugh
Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression
Rheumatology, June 1, 2009; 48(6): 607 - 612.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
E. C. Derrett-Smith and D. A. Isenberg
Autoimmunity manifesting as dermatomyositis associated with oligoastrocytoma and dendritic cell immunotherapy
Rheumatology, July 1, 2008; 47(7): 1101 - 1102.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
H. Gunawardena, L. R. Wedderburn, J. North, Z. Betteridge, J. Dunphy, H. Chinoy, J. E. Davidson, R. G. Cooper, N. J. McHugh, and for the Juvenile Dermatomyositis Research Group UK
Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis
Rheumatology, March 1, 2008; 47(3): 324 - 328.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
L. R. Wedderburn, N. J. McHugh, H. Chinoy, R. G. Cooper, F. Salway, W. E. R. Ollier, L. J. McCann, H. Varsani, J. Dunphy, J. North, et al.
HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis scleroderma overlap
Rheumatology, December 1, 2007; 46(12): 1786 - 1791.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.